Bayer contraceptives business
PE-OWNED
Acquired by Apollo Global
What PE Will Likely Do
Reduction in R&D spending for next-generation contraceptive formulations, leading to fewer product improvements and delayed safety updates
Price increases of 15-40% on established products like Yaz, Yasmin, and Mirena as Apollo seeks to maximize cash extraction from captive patient base
Reduction in patient support programs, including elimination of copay assistance cards and fertility counseling services
Consolidation of manufacturing facilities leading to supply chain disruptions and periodic stockouts at pharmacies
Deferred maintenance and delayed upgrades to quality control systems, increasing risk of batch recalls
Expected Timeline
“0 to 6 months months”
Announcements about 'optimizing global operations' and 'enhancing shareholder value'; quiet elimination of patient assistance programs; initial price increases disguised as 'market adjustments'
“6 to 12 months months”
First manufacturing facility closures announced; reduction in medical affairs staff; physicians report difficulty reaching company representatives; supply shortages begin in select markets
“12 to 24 months months”
Noticeable increase in FDA warning letters or quality citations; patient complaints about insurance coverage denials rise; reduction in clinical trial commitments for existing products; emergence of generic competition exploited rather than competitively countered
“24 to 48 months months”
Rumors of business unit sale or spin-off; further price escalation; potential elimination of non-core products (e.g., specific IUD sizes, lower-dose formulations with smaller patient populations); deferred maintenance triggers quality incidents
What You Can Do
Actions
Stockpile 6-12 month supply of current preferred contraceptive if switching is medically difficult, before manufacturing changes or supply disruptions
Request specific manufacturer information from pharmacy and refuse substitution if switched to different production facility
Document baseline side effects and efficacy now to compare against any future formulation changes
Investigate whether current prescription is for originator product or already-licensed generic; if originator, research whether generic alternatives have equivalent clinical data
Contact healthcare provider about alternative long-acting reversible contraceptives (IUDs, implants) from manufacturers not owned by Apollo if concerned about future supply reliability
Alternatives
Look for family-owned or employee-owned businesses